Oncology On The Go

Starting April 1, 2024, Diane M. Simeone, MD will start her new position as director of the University of California San Diego (UCSD) Health Moores Cancer Center.1  In a conversation with CancerNetwork ®, Simeone highlighted her excitement to be working with an institution that she said aligns with her goals and values. During her time as director, she said that she wants to focus more on early de...

After the 2024 Gastrointestinal Cancers Symposium, Jun Gong, MD, and Daneng Li, MD, sat down to discuss the most relevant trial data to have come from the conference. They convened for a live X Space hosted by CancerNetwork®. During the discussion, they covered different trials across the gastrointestinal space, which included those evaluating different disease states from hepatocellular carcinoma...

In a conversation with CancerNetwork ®, Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, spoke about factors that may contribute to feelings of stigmatization surrounding a lung cancer diagnosis, which may impact an individual’s decision to undergo screening for potential disease. Specifically, Carter-Bawa, director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Healt...

Although strides have been made with Bruton tyrosine kinase (BTK) inhibitors and CAR-T cell therapy, relapse and resistance remain significant hurdles in treating patients with mantle cell lymphoma (MCL). The Lymphoma Research Foundation's 2023 MCL Scientific Consortium and Workshop addressed these complexities, aiming to dissect the intricate biology of MCL and propel progress towards a cure. Can...

Integrative therapies have been proven to help reduce the adverse effects (AEs) of anxiety and depression in patients with cancer, according to Linda E. Carlson, PhD, RPsych.  Carlson, Enbridge Research Chair in Psychosocial Oncology and a professor in the Department of Oncology, Cumming School of Medicine at the University of Calgary, explained how different therapies such as mindfulness-based in...

In a conversation with CancerNetwork® prior to the FDA approval of pembrolizumab (Keytruda) plus chemoradiotherapy in FIGO stage III to IVA cervical cancer, Jyoti S. Mayadev, MD, spoke about how the regimen’s approval would be a “major step” for the aforementioned population and how she planned to integrate it into her care.1  Mayadev, a board-certified radiation oncologist and professor of radiat...

In a conversation with CancerNetwork®, Sarah Donahue, MPH, NP, discussed strategies for managing adverse effects (AEs) associated with different drug classes for patients with metastatic breast cancer, ranging from antibody drug conjugates (ADCs) to CDK4/6 inhibitors. With respect to ADCs, Donahue, a nurse practitioner at University of California, San Francisco, and member of the Oncology Nursing...

In a recent conversation with CancerNetwork®, Sara A. Hurvitz, MD, FACP, senior vice president and director of the Clinical Research Division at Fred Hutch Cancer Center and head of the Division of Hematology and Oncology at the University of Washington Department of Medicine, discussed new treatment options for patients with metastatic HER2-positive breast cancer.  In the discussion, Hurvitz high...

In a conversation with CancerNetwork®, Amy Tiersten, MD, spoke about how findings from the phase 1/2 ASPIRE trial (NCT03304080) may support anastrozole (Arimidex) plus palbociclib (Ibrance), trastuzumab (Herceptin), and pertuzumab (Perjeta) as a first-line treatment for patients with hormone receptor (HR)–positive, HER2-positive metastatic breast cancer. Data presented at the 2023 San Antonio Brea...

In a conversation with CancerNetwork®, Rakshanda Rahman, MD, FRCS, FACS, discussed a wide range of surgical therapy strategies and other developments in the breast cancer space, ranging from factors that should be considered for surgical decision-making to the evolution of artificial intelligence (AI) in the field. Rahman, a professor of Breast Surgical Oncology at Texas Tech University Health Sci...

In a recent discussion with CancerNetwork®, Joleen Hubbard, MD, research collaborator with Mayo Clinic and deputy director for clinical research at Allina Health Cancer Institute in Minneapolis, Minnesota, discussed new opportunities for patients with colorectal cancer (CRC).   In the discussion, Hubbard highlighted the potential of trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in patients with HER...

CancerNetwork® spoke with Govindarajan Narayanan, MD about his practice becoming the first in the United States to successfully surgically treat a patient with a liver tumor using the Epione robot, as well as the process of transitioning from CT-based image guidance to the robotic workstation in his care.1  Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and...

During an overview of the current standard of care for patients with colorectal cancer (CRC) , Tanios S. Bekaii-Saab, MD noted that as molecular testing becomes more important, researchers are looking into how to best personalize therapy for optimal outcomes. He spoke with CancerNetwork® as part of an Around the Practice® program focused on testing and treatment options for patients with metastati...

Kristen K. Ciombor, MD, MSCI, an assistant professor in the Division of Hematology/Oncology in the Department of Medicine at the Vanderbilt University Medical Center, recently spoke at an Around the Practice discussion regarding updates in the world of metastatic colorectal cancer (CRC). In this episode of the ONCOLOGY® On the Go Podcast, she discusses treatment updates, molecular testing options,...

As part of an Around the Practice program, CancerNetwork® spoke with Misako Nagasaka, MD, PhD, about her current treatment strategies for patients with lung cancer as well as relevant updates and potential advancements in the non–small cell lung cancer (NSCLC) space. Nagasaka, a thoracic oncologist and associate clinical professor at the University of California, Irvine, discussed sequencing immun...

Sexual dysfunction is a common problem for patients with and survivors of cancer that often remains undertreated. It can manifest in a variety of ways, including reduced libido, sexual pain, and vaginal dryness. Jennifer A. Vencill, PhD, LP, takes a biopsychosocial approach to sexual health, helping to address the psychological aspects of sexual dysfunction. In this episode of the ONCOLOGY On the...

During Breast Cancer Awareness Month 2023,   Rebecca M. Shulman, MD, an assistant professor in the Department of Radiation Oncology at Fox Chase Cancer Center, and Zachary Kiss, DO, a third-year resident physician in radiation oncology at Fox Chase, spoke about findings from their study, which assessed how BRCA1/2 mutations in patients with breast cancer do not appear to affect treatment outcomes...

In this episode of  the ONCOLOGY On the Go Podcast, Arvind N. Dasari, MD, and Cathy Eng, MD, speak to data supporting fruquintinib (Elunate), a VEGFR-1, -2, and -3 inhibitor as a potential treatment for patients with metastatic colorectal cancer (CRC). Dasari is an associate professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Tex...

CancerNetwork® spoke with experts across multiple disciplines about the far-reaching impacts of the ongoing shortages of chemotherapy drugs including carboplatin and cisplatin, and how practices may be able to mitigate these challenges in the short and long term.  Michael Ganio, PharmD, MS, BCPS, FASHP, described the causes of carboplatin and cisplatin being in short supply across the United State...

As part of a CancerNetwork® Frontline Forum program, Alexander I. Spira, MD, PhD, FACP; Millie Das, MD; Joshua K. Sabari, MD; and Misako Nagasaka, MD, PhD, reviewed updates in the management of EGFR exon 20 non–small cell lung cancer (NSCLC), and how these findings may apply to clinical practice.  Spira, codirector of the Virginia Cancer Specialists Research Institute and director of the Thoracic...

As part of a CancerNetwork® Frontline Forum program, Joselle Cook, MBBS; Matthew James Pianko, MD; Luciano Costa, MD, PhD; and Timothy Schmidt, MD, reviewed key data updates and real-world practice findings in newly diagnosed multiple myeloma (NDMM), and how they may impact patient subgroups including those with transplant-ineligible NDMM. Cook, a hematologist specializing in the management of pat...

In a Twitter Spaces edition of the Oncology-On-The-Go podcast, Rafael Fonseca, MD and Krina Patel, MD, MSc spoke with CancerNetwork® about how key findings from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting may impact the treatment paradigm.  Fonseca, director of Innovation and Transformation Relationships at the Mayo Clinic in Phoenix, A...

In a conversation with CancerNetwork® during July’s Sarcoma Awareness Month 2023 , Brian Van Tine, MD, PhD, spoke about developments in the sarcoma research space and discussed where future research needs to be focused in order to push the needle forward in the treatment of this patient across numerous sarcoma subgroups. Van Tine, a professor of medicine in the Division of Oncology, Section of Med...

In a conversation with CancerNetwork® during June’s National Cancer Survivor Month, Lindsay Morton, PhD, spoke about her research on the long-term risks of developing second cancers among cancer survivors. Morton, director of the Radiation Epidemiology Branch and head of the Cancer Survivorship Research Unit at the National Cancer Institute and member of the Lymphoma Research Foundation’s Scientif...

Ritu Salani, MD, and Tanios S. Bekaii-Saab, MD, FACP, spoke with CancerNetwork® about key findings presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , and how they may affect clinical practice for gynecologic cancer and gastrointestinal cancer. Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles (UCLA) Health and the Gynecolo...